The purpose of the present experiment was to determine if there is a factor in serum of patients with myasthenia gravis (MG) that interferes with binding of (125I)-alpha-bungarotoxin to acetylcholine receptors of normal mouse diaphragm. Diaphragms were incubated aerobically for 1 hour in either Krebs-Henseleit solution, MG serum, or control serum, and then (125I)-alpha bungarotoxin was added for 2 further hours at a concentration of 1 mug/ml. After 12 rinses in Krebs-Henseleit solution for another hour, radioactivity was counted. Binding after exposure to MG serum was compared to that obtained after exposure to Krebs-Henseleit solution or control serum. Sixteen sera from 14 controls, 18 sera from 15 patients with moderate generalized MG, and seven sera from seven patients on alternate-day prednisone therapy (six with severe generalized MG, one with myasthenic syndrome) were tested by this method. No significant difference in alpha-bungarotoxin binding was observed between normal mouse diaphragm incubated in MG sera and those incubated in control sera.
No takes yet. Share an insight, caveat, or question.
Keesey et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: